

Please use only the valid version of the package insert provided with the kit.

Intended Use

The PARAINFLUENZA-1/2/3 ELISA has been designed for the detection and the quantification of specific IgG / IgM / IgA antibodies respectively against Parainfluenza virus type 1/2/3 in serum and plasma. Further applications in other body fluids are possible and can be provided on request.

This assay is intended for *in-vitro* use only.

All laboratory test results should be interpreted in conjunction with other clinical data. The clinical judgement and further tests have to be taken into account additionally.

Introduction

The infection with parainfluenza viruses is air-borne from man-to-man. Various species of animals may serve as virus reservoir. Parainfluenza viruses are endemically spread world-wide. The seroprevalence of parainfluenza in infants in their first year of life is 50 %. Typical for parainfluenza viruses are frequent re-infections, this applies particularly to parainfluenza 3 viruses. Incubation time is 2–6 days.

The parainfluenza viruses are a subgroup of the paramyxoviruses. They are of the same size of approximately 150–300 nm. They are ether-sensitive, agglutinate human or chicken erythrocytes and have a receptor-destructive enzyme, as known from influenza viruses. They can be cultivated best in primary monkey cell cultures or in human epithelia cell cultures, however, less successful in embryonized chicken eggs. It is differentiated between parainfluenza 1, 2, 3 and 4.

Together with the respiratory syncytial viruses (RSV), the pathogens belong to the major viral pathogens for diseases of the respiratory tract, accompanied by severe clinical symptoms. In adults, parainfluenza virus causes a feverish rhinitis and laryngitis. First signs are sudden headaches, pain in muscles and joints, followed by fever of 38–39 °C. If the lower respiratory tract is involved, additionally trachyphonia and dry cough develops as a sign of tracheobronchitis.

Parainfluenza-1 causes severe pneumonias in newborns, manifested by high fever, cyanosis, dyspnoea and bloody purulent sputum. Sometimes, meningitis symptoms occur at the same time.

Parainfluenza-2 very often causes an acute laryngotracheobronchitis with pseudocroup in infants and children.

First signs of the infection are catarrhal symptoms, followed by trachyphonia, dry barking cough and inspiratory stridor.

Parainfluenza-3 viruses are considered the major pathogens of pneumonia and bronchiolitis.

While types 1, 2 and 3 are distributed worldwide, parainfluenza type 4 appears only in the USA. Infections 1 and 3 occur all the year, while parainfluenza 2 and 4 viruses appear only sporadically.

Laboratory diagnosis of parainfluenza viruses is done with haemagglutination inhibiting test (HIT) complement binding reaction (CF) and neutralisation test (NT). Newer methods are IFA and ELISA, which allow identification of IgG and IgA antibodies in patient serum. In differential diagnosis, tests for other paramyxoviruses like mumps, shipping fever viruses and simianvirus type 5 have to be performed due to possible cross-reactions.

Revised 26 Aug. 2009 (Vers. 2.0)

Principle of the Test

The principle of the test reaction can be described in four stages.

3.1 Serum incubation: Specific antibodies bind to the antigens on the solid phase to form a stable immune complex. After a 60 minutes incubation at room temperature the wells are washed with prediluted wash buffer to remove all non-reactive serum components.

3.2 Conjugate incubation: The anti-human-IgG /-IgM /-IgA horseradish peroxidase conjugate is added to all wells. The conjugate binds to IgG / IgM / IgA antibodies on the solid phase antigen to form a stable sandwich. After a 30 minutes incubation at room temperature the excess conjugate is removed by washing all wells with washing buffer.

3.3 Substrate reaction and stopping: The TMB substrate is dispensed into each well and the peroxidase enzyme/substrate reaction forms a stable blue chromogen. The reaction and subsequently the colour development is stopped after 20 minutes incubation at room temperature by adding 0.5 M H₂SO₄ to the wells. The change in pH also causes the chromogen to change colour from blue to yellow.

3.4 Reading and interpretation: The intensity of the colour is read in a microtiter plate reader at 450 nm (recommended reference wavelength for bichromatic measurement: 600–690 nm). The intensity of the colour (OD) is directly proportional to the concentration of the specific antibody in the patient sample.

Kit Contents

The kits contains sufficient reagents for 12 x 8 = 96 determinations. The strips and solutions have to be stored at 2–8 °C. The expiry date is mentioned on the labels.

12 strips **Microtiter strips** single strips each with 8 break-apart wells coated with antigen of Parainfluenza virus type 1/2/3 virus

1 x **Frame holder**

4 x 2 mL **Standard 1–4** human serum containing antibodies against Parainfluenza virus type 1/2/3 (concentrations listed below) diluted in PBS and stabilised with 0.01 % methylisothiazolone and 0.01 % bromonitrodioxane as preservatives, ready to use

		IgG	IgM	IgA
Std. 1 (negative)	Concentration (U/mL)	1	1	1
Std. 2 (cut-off)		10	10	10
Std. 3 (weak positive)		30	40	40
Std. 4 (positive)		125	200	100

1 x 60 mL **Serum Diluent** PBS/BSA buffer solution, contains < 0.1 % sodium azide as preservative, ready to use

1 x 12 mL **Enzyme Conjugate** HRP-labelled goat anti-human-IgG /-IgM /-IgA, ready to use

1 x 12 mL **TMB Substrate** 3,3',5,5' Tetramethylbenzidine, ready to use

Revised 26 Aug. 2009 (Vers. 2.0)

1 x 12 mL	Stop Solution	0.5 M sulfuric acid, ready to use
1 x 60 mL	Wash Buffer	PBS/Tween buffer solution <u>10x concentrated</u> to be diluted 1:10 prior to use; the concentrate should be warmed up to 37 °C for 15 minutes to avoid any crystals
2 x	Plate sealers	to cover microtiter strips during incubation
1 x	Plastic bag	re-sealable for dry storage of non-used strips

Materials Required but not Provided

5 µL-, 100 µL- and 500 µL micro- and multichannel pipets
Microtiter plate reader with a 450 nm filter (reference filter 600–690 nm)
Microtiter Plate Washer (in case of manual washing: wash bottle)
Reagent tubes for the serum dilution
Measuring cylinder
Distilled water or water of higher quality

Warning and Precautions

- o For *in-vitro* use only! Do not ingest or swallow! Laboratory safety precautions should be followed. Do not eat, drink or smoke in the laboratory.
- o All sera and plasma or buffers based upon have been tested to HBsAg, HIV and HCV respectively with generally accepted methods and were found negative. Nevertheless, precautions like the use of latex gloves have to be taken.
- o Serum and reagent spills have to be wiped off with a disinfecting solution (e.g. sodium hypochlorite 5 %) and have to be disposed of properly.
- o All reagents have to be brought to room temperature (18–24 °C) before performing the test.
- o Before pipetting all reagents should be mixed thoroughly by gentle tilting or swinging. Vigorous shaking with formation of foam should be avoided.
- o It is important to pipet with constant intervals so that all the wells of the microtiter plate have the same conditions.
- o When removing reagents out of the bottles care has to be taken that the stoppers are not contaminated. Further a possible mix-up has to be avoided. The content of the bottles is usually sensitive to oxidation so that they should be opened only for a short time.
- o In order to avoid a carry-over or a cross-contamination separate disposable pipet tips have to be used.
- o No reagents from different kit lots should be used and they should not be mixed with one another.
- o All reagents have to be used within shelf life.

Revised 26 Aug. 2009 (Vers. 2.0)

- o In accordance with a Good Laboratory Practice (GLP) or following ISO 9001 all laboratory devices employed should be regularly checked regarding the accuracy and precision. This refers e.g. to microliter pipets and washing or reading (ELISA Reader) instrumentation.
- o The contact of certain reagents especially the stopping solution and the substrate with skin, eye and mucosa has to be avoided because possible irritations and acid burns could arise and there exists a danger of intoxication.

Storage and Stability

Store all reagents at 2–8 °C.

The expiry date of each reagent is printed on the individual labels. Do not use any reagents after the expiry date has been exceeded.

The diluted washing buffer is stable for up to 4 weeks when stored at 2–8 °C.

The opened kit should be used within three months.

Specimen Collection and Handling

Both serum or plasma (EDTA, heparin) can be used for the determination.

Serum is separated from the blood which is aseptically drawn by venipuncture after clotting and centrifugation.

The serum or plasma samples can be stored at 2–8 °C for up to 3 days. They should be kept at -20°C for a longer storage. The samples should not be frozen and thawed repeatedly.

Lipemic, hemolytic or bacterially contaminated samples can cause false positive or false negative results.

Patient sera must be **prediluted 1:101** in *Serum Diluent* (e.g. 5 µL serum + 500 µL *Serum Diluent*) prior to testing.

Samples containing concentrations higher than the highest standard have to be diluted further with *Serum Diluent*.

In case of interference with rheumatic factors, serum preabsorption with RF absorbent (SORB  651003) is recommended. **Do not absorb the standards.**

Assay Procedure

Preparation of Reagents

Allow all kit components and specimens to reach room temperature (RT, 18–24 °C) prior to use and mix well.

Washing buffer:

Dissolve any crystals which may be in the bottle by warming to 37 °C and then mix well.

Dilute the concentrated washing buffer **1:10** with distilled water (e.g. 60 mL buffer concentrate + 540 mL distilled water). Mix thoroughly.

Revised 26 Aug. 2009 (Vers. 2.0)

Strictly follow the instructions for reliable test performance. Any changes or modifications are within the responsibility of the user.

All reagents and samples must be brought to room temperature before use, but should not be left at this temperature for longer than necessary.

A standard curve should be established with each assay.

Put the unused microtiter strips back in the plastic bag and store them dry at 2–8 °C.

Assay Steps

Prepare a sufficient amount of microtiter wells for standards, controls and samples.

Note: Other incubation conditions might be possible. In case of modifications of the recommended test procedure (e.g. incubation temperature 37 °C instead of RT) the user has to validate assay performance.

1. Pipette 100 µL each of the diluted (1:101) samples and the ready to use standards into the appropriate wells.
2. Cover plate with the enclosed plate sealing foil and incubate at room temperature for 60 minutes.
3. Discard the contents of the microwells and wash 3 times with 300 µL of diluted washing buffer. Afterwards remove residues of the washing solution by gentle tapping of the microtiter plate on a paper towel.
4. Pipette 100 µL of *Enzyme Conjugate* solution into each well.
5. Cover plate with plate sealing foil and incubate for 30 minutes at room temperature.
6. Discard the contents of the microwells and wash 3 times with 300 µL of diluted washing buffer. Afterwards remove residues of the washing solution by gentle tapping of the microtiter plate on a paper towel.
7. Dispense 100 µL of *TMB Substrate* into each well.
8. Cover plate with the plate sealing foil and incubate for 20 minutes in the dark (e.g. drawer) at room temperature.
9. Add 100 µL of *Stop Solution* to each well.
10. After thorough mixing and wiping the bottom of the plate, read the optical density at 450 nm and calculate the results. Blank against air. A bichromatic measurement using a reference wavelength of 600–690 nm is recommended.

The developed colour is stable for at least 60 minutes. Read optical densities during this time.

Results and Interpretation

Example

	OD 450 nm	corrected OD	Mean OD Value
Blank	0.008		
Standard 1 (negative)	0.024 / 0.020	0.016 / 0.012	0.014
Standard 2 (cut-off)	0.647 / 0.634	0.639 / 0.626	0.633
Standard 3 (weak positive)	1.428 / 1.439	1.420 / 1.431	1.426
Standard 4 (positive)	2.238 / 2.276	2.230 / 2.268	2.249

The table above should be considered as an example which was achieved under arbitrary temperature and environmental conditions. **These data do NOT describe reference values which have to be found in other laboratories in the same way!**

Qualitative Calculation

The calculated OD values for patient sera as mentioned above are compared with the value for the cut-off standard. If the value of the sample is higher, then it should be read as **positive**.

A value below the cut-off standard should be read as **negative**.

It seems reasonable to define a range of $\pm 20\%$ around the value of the cut-off as a **grey zone**. It is recommended to repeat results laying within the grey zone using the same serum or a new sample of the same patient, taken after 2–4 weeks. Both samples should be measured in parallel in the same run.

The positive standard must show an absorption value at least double the value received by the cut-off standard.

Quantitative Calculation

The ready to use standards of the Parainfluenza virus type 1/2/3 antibody kits are defined and values expressed are in arbitrary units (U/mL). This gives access to an exact and reproducible quantification and in consequence patient antibody titer monitoring is possible. Concentration values for standards are printed on the labels of the vials.

A standard curve is plotted by entering the mean absorbance value of the standards on the Y-axis and the corresponding concentration on the X-axis using graph paper. The concentration of the patient samples can then be read directly from the graph.

The calculation of the result can be performed using a computer and a suitable software program.

Assay Performance

The assay characteristics of the PARAINFLUENZA-1/2/3 IgG / IgM / IgA ELISA's have been established and assessed according the European IVD directive. Detailed validation data can be provided on special request.

References

1. Collins PL, Chanock RM, McIntosh K. Parainfluenza viruses, in Fields BN (ed): Fields Virology. Philadelphia, Lippincott-Raven Publishers pp 1205-1241(1996).
2. Chanock RM. Association of a new type of cytopathogenic myxovirus with infantile croup. J Exp Med 104: 555-576, (1956).
3. Andrewes CH, Bang FB, Chanock RM, et al. Parainfluenza viruses 1, 2, and 3: Suggested names for recently described myxoviruses. Virology 8: 129-130, (1959).
4. Hotez PJ, Doveikis SA. Adult respiratory distress syndrome associated with parainfluenza virus type 1 in children. Pediatr Infect Dis J 9: 750-752, (1990).
5. Monto AS. The Tecumseh study of respiratory illness: V: Patterns of infection with the parainfluenza viruses. Am J Epidemiol 97: 338-348, (1973).
6. Hornsleth A. Respiratory virus disease in infancy and childhood in Copenhagen 1963-65: an estimation of the etiology based on complement fixation tests. Acta Pathol Microbiol Scand 69: 287-303, (1967).
7. Killgore GE, Dowdle WR. Antigenic characterization of parainfluenza 4a and 4b by the hemagglutination-inhibition test and distribution of HI antibody in human sera. Am J Epidemiol 91: 308-316, (1970).
8. LaPlaca M, Moscovici C. Distribution of parainfluenza antibodies in different groups of population. J Immunol 88: 72-77, (1962).
9. Fan J, Henrickson KJ. Rapid diagnosis of human parainfluenza virus type 1 infection by quantitative reverse transcription-pcr-enzyme hybridization assay. J Clin Microbiol 34: 1914-1917, (1996).
10. Karron RA, Wright PF, Hall SL, et al: Live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis 171: 1107-1114, (1995).

Revised 26 Aug. 2009 (Vers. 2.0)

Symbols used with DRG Assays

Symbol	English	Deutsch	Français	Español	Italiano
	Consult instructions for use	Gebrauchsanweisung beachten	Consulter les instructions d'utilisation	Consulte las instrucciones de uso	Consultare le istruzioni per l'uso
	European Conformity	CE-Konformitätskennzeichnung	Conformité aux normes européennes	Conformidad europea	Conformità europea
	In vitro diagnostic device	In-vitro-Diagnostikum	Usage Diagnostic in vitro	Para uso Diagnóstico in vitro	Per uso Diagnostica in vitro
	For research use only	Nur für Forschungszwecke	Seulement dans le cadre de recherches	Sólo para uso en investigación	Solo a scopo di ricerca
	Catalogue number	Katalog-Nr.	Numéro de catalogue	Número de catálogo	Numero di Catalogo
	Lot. No. / Batch code	Chargen-Nr.	Numéro de lot	Número de lote	Numero di lotto
	Contains sufficient for <n> tests/	Ausreichend für "n" Ansätze	Contenu suffisant pour "n" tests	Contenido suficiente para <n> ensayos	Contenuto sufficiente per "n" saggi
	Storage Temperature	Lagerungstemperatur	Température de conservation	Temperatura de conservación	Temperatura di conservazione
	Expiration Date	Mindesthaltbarkeits-datum	Date limite d'utilisation	Fecha de caducidad	Data di scadenza
	Legal Manufacturer	Hersteller	Fabricant	Fabricante	Fabbricante
Distributed by	Distributor	Vertreiber	Distributeur	Distribuidor	Distributore
Content	Content	Inhalt	Conditionnement	Contenido	Contenuto
Volume/No.	Volume / No.	Volumen/Anzahl	Volume/Quantité	Volumen/Número	Volume/Quantità

Symbol	Portugues	Dansk	Svenska	Ελληνικά
	Consulte as instruções de utilização	Se brugsanvisning	Se bruksanvisningen	Εγχειρίδιο χρήστη
	Conformidade com as normas europeias	Europæisk overensstemmelse	Europeisk överensstämmelse	Ευρωπαϊκή Συμμόρφωση
	Diagnóstico in vitro	In vitro diagnostik	Diagnostik in vitro	in vitro διαγνωστικό
				
	Catálogo n.º	Katalognummer	Katalog nummer	Αριθμός καταλόγου
	No do lote	Lot nummer	Batch-nummer	Αριθμός Παρτίδος
		Indeholder tilstrækkeligt til "n" test	Innehåller tillräckligt till "n" tester	Περιεχόμενο επαρκές για «n» εξετάσεις
	Temperatura de conservação	Opbevarings-temperatur	Förvaringstemperatur	Θερμοκρασία αποθήκευσης
	Prazo de validade	Udløbsdato	Bäst före datum	Ημερομηνία λήξης
	Fabricante	Producent	Tillverkare	Κατασκευαστής
Distributed by				
Content	Conteúdo	Indhold	Innehåll	Περιεχόμενο
Volume/No.	Volume/Número	Volumen/antal	Volym/antal	Όγκος/αριθμ..